Business Context and Reporting Period
This Form 10-Q covers the quarterly and nine-month periods ended September 28, 2001, for Wilson Greatbatch Technologies, Inc. (Note: The request metadata listed "Integer Holdings Corp," but the filing text explicitly identifies the registrant as Wilson Greatbatch Technologies, Inc.). The company is a leading developer and manufacturer of power sources and components for implantable medical devices (pacemakers, ICDs) and specialty batteries for commercial applications (aerospace, oil and gas).
Key Financial Metrics
| Metric | Three Months Ended Sept 28, 2001 | Nine Months Ended Sept 28, 2001 |
|---|---|---|
| Revenues | $38.3 million | $100.9 million |
| Gross Profit | $16.6 million (43% margin) | $45.3 million (45% margin) |
| Net Income (Loss) | $3.3 million | $5.9 million |
| Diluted EPS | $0.16 | $0.30 |
| Cash and Equivalents | $43.6 million (Balance Sheet) | $43.6 million (Balance Sheet) |
| Operating Cash Flow | N/A | $10.6 million |
| Total Debt | $80.4 million (Current + Long-term) | $80.4 million (Current + Long-term) |
Debt Structure: The company maintains a $100.0 million credit facility consisting of an $80.0 million term loan and a $20.0 million revolving line of credit. As of September 28, 2001, $80.0 million was outstanding on the term loan with no balance on the revolving line. The weighted average interest rate was 6.0%.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 65% ($15.0 million) for the quarter and 44% ($31.0 million) for the nine months compared to the prior year. This growth was driven by the acquisition of Sierra-KD Components (June 2001) and Battery Engineering, Inc. (BEI), alongside organic growth in pacemaker and ICD battery sales.
- Profitability Turnaround: The company reported a net income of $3.3 million for the quarter, reversing a net loss of $0.9 million in the same period in 2000. For the nine months, net income was $5.9 million versus a loss of $1.6 million in 2000.
- Interest Expense Reduction: Interest expense dropped 70% for the quarter and 78% for the nine months, primarily due to debt restructuring in January 2001 and lower interest rates on the new credit facility.
- Extraordinary Loss: The nine-month period included a one-time extraordinary loss of $3.0 million (net of tax) related to the retirement of previous senior debt and subordinated notes in January 2001.
Guidance, Outlook, and Risks
Management Commentary: Management attributes the improved results to higher manufacturing volumes, successful integration of acquisitions, and reduced interest costs. Capital expenditures for 2001 are projected at $8.0 million to $9.0 million.
Accounting Changes: The company is preparing for the adoption of SFAS No. 142 (Goodwill and Other Intangible Assets) effective December 29, 2001. This will cease the amortization of goodwill (approx. $1.4 million for the nine months) and assembled workforce, potentially increasing future reported earnings, though an impairment test will be required.
Risks and Contingencies:
- Customer Concentration: Dependence on a limited number of customers in the medical device industry.
- Market Risk: A 10% change in short-term interest rates could impact 2001 earnings by approximately $0.5 million.
- Regulatory and Integration: Risks related to healthcare industry consolidation, regulatory changes, and the successful integration of recent acquisitions.
Investor Verification Checklist
- Acquisition Impact: Verify the specific contribution of the Sierra-KD acquisition to Q3 revenue and the timeline for full integration benefits.
- Debt Covenants: Review the specific EBITDA and leverage ratios required by the $100 million credit facility to ensure compliance.
- Goodwill Impairment: Monitor the upcoming SFAS No. 142 adoption for potential goodwill impairment charges that could offset the benefit of ceased amortization.
- Customer Concentration: Assess the risk profile regarding the top customers in the implantable medical device sector.
- Cash Flow Sustainability: Confirm that operating cash flow ($10.6M YTD) remains sufficient to cover the $80M debt service and planned capital expenditures without further equity dilution.